The the purpose of the phase II program is to focus on developing a t-cell activation protocol consistent with reportercell viability, developing a proprietary reporter cell line and gathering and…
Ended Definitive Contract Awarded Last action
- Contract number
- 75N93020C00050
- Awardee
-
Cell Microsystems Inc. UEI G51EN7YDH7F3
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,648,645
Award facts
- Opportunity
-
- NIHAI20181 Solicitation number
- High-throughput Latent HIV Reservoir Assay Using Microwell Arrays Award Notice · Posted Aug 13, 2020
- Contract value 100% obligated
- $1,648,645.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 1 offer Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Durham, NC 27713, USA
- Research
- SBIR Program Phase II Action
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $1,648,645 |
About this award
This is a $1,648,645.00 Firm Fixed Price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, to Cell Microsystems Inc. under the Small Business Innovation Research (SBIR) Phase II program. The purpose of this contract is to focus on developing a T-cell activation protocol consistent with reporter cell viability, creating a proprietary reporter cell line, and gathering and benchmarking patient-derived samples with the QVOA (Quantitative Viral Outgrowth Assay) method. This contract, which has a completion date of April 12, 2023, is a total small business set-aside.
Description
The the purpose of the phase II program is to focus on developing a t-cell activation protocol consistent with reportercell viability, developing a proprietary reporter cell line and gathering and benchmarking patient derived samples withthe qvoa met
Quick answers
Who was awarded contract 75N93020C00050?
75N93020C00050 was awarded to Cell Microsystems Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 13, 2020.
How much is contract 75N93020C00050 worth?
The government has obligated $1,648,645 on 75N93020C00050.
Was contract 75N93020C00050 competed?
The extent of competition for 75N93020C00050 was full and open competition after exclusion of sources. The government received 1 offer. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award